Clinical Validation of Myriad Genetics’ Ultra-Sensitive Pan-Cancer WGS-Based Precise MRD Assay

12:30 pm - Tuesday 21st July 2026

  • Join this deep-dive session to understand how ultra-sensitive, tumor-informed MRD testing is being applied across clinical and development settings
  • Walk away with a clear view of where ultra-sensitive MRD testing delivers value today 
  • Understand how to apply it across your own programs

Speakers:

Senior Vice President, R&D
Myriad Genetics